Illumina names Agilent executive as new CEO
Illumina Inc. (ILMN) on Tuesday announced that its board has appointed Agilent Technologies Inc. (A) senior vice president Jacob Thaysen as its new CEO, effective Sept. 25. The DNA sequencing company faced leadership turmoil after its proxy fight earlier this year with activist investor Carl Icahn, and CEO Francis deSouza stepped down in June. Evercore ISI analysts wrote in a research note last week that Illumina shares could be poised for a turnaround under new leadership, noting that "new CEOs can be powerful catalysts." Thaysen's "extensive background and experience in genomics, life sciences, and technology fits closely with Illumina's mission," the company said in a statement Tuesday, adding that the executive since 2018 has overseen the unit responsible for Agilent's analytical instrument portfolio, informatics, and cell analysis franchise. Illumina shares gained 0.6% premarket on Tuesday and have declined 16.7% in the year to date, while the S&P 500 has gained 17.6%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-05-23 0746ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks